AbbVie Inc (ABBV)vsOmada Health, Inc. Common Stock (OMDA)
ABBV
AbbVie Inc
$201.55
-0.57%
HEALTHCARE · Cap: $358.55B
OMDA
Omada Health, Inc. Common Stock
$14.82
-9.63%
HEALTHCARE · Cap: $974.41M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 24042% more annual revenue ($62.82B vs $260.21M). ABBV leads profitability with a 5.8% profit margin vs -4.9%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
OMDA
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-19.7%
Fair Value
$168.33
Current Price
$201.55
$33.22 premium
Margin of Safety
+41.8%
Fair Value
$18.79
Current Price
$14.82
$3.97 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 58.1% year-over-year
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 4.3%
ROE of -8.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : OMDA
The strongest argument for OMDA centers on Revenue Growth. Revenue growth of 58.1% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Bear Case : OMDA
The primary concerns for OMDA are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while OMDA is a hypergrowth play — different risk/reward profiles.
OMDA is growing revenue faster at 58.1% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 37/100) and 12.4% revenue growth. OMDA offers better value entry with a 41.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Omada Health, Inc. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Omada Health, Inc. provides a range of virtual care programs in the United States. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?